Iovance Stock Surges as Strong Melanoma Drug Demand Drives Growth — Barrons.com

By Ty RoushShares of Iovance Biotherapeutics surged Tuesday after the biotech company raised its fiscal-year revenue guidance, thanks to rising demand for a pair of melanoma treatments.Iovance stock rose 28% to $14.06, pacing toward its highest close since May 7, 2024, when shares reached $13.98, a…